



FluMist – protection without the injection¹

Individual results may vary.

Together, we can help protect more patients



Some patients may not be able to visit your office—yet they still need flu protection. FluMist offers an option for at-home delivery and self- or caregiver administration for the 2025-2026 flu season.¹

FluMist can be delivered to patients through FluMist Home.



It's the same proven FluMist nasal spray vaccine¹

FluMist is for the prevention of influenza in persons 2-49 years of age



It's a convenient option to help prevent the flu in eligible patient ages 2-49^{1*}

A caregiver should administer FluMist to individuals ages 2-17

Individual results may vary



FluMist will also remain available in offices and in pharmacies for administration by an HCP

With only 49.2% of children aged 6 months-17 years vaccinated against the flu, and only 36.3% of adults aged 18-49 years vaccinated against the flu,^{2,3†} **it's important to offer options for vaccination.** You serve as a trusted source of information, so discuss how vaccination against the flu can help play a crucial role in helping patients stay healthy.

HCP=healthcare professional, CDC=Centers for Disease Control and Prevention

*Local restrictions may apply.

†2024-2025 CDC influenza vaccination coverage rates as of April 26, 2025.

IMPORTANT SAFETY INFORMATION

- Do not administer FLUMIST to persons who have had a severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine, or to children and adolescents through 17 years of age who are receiving aspirin or aspirin-containing therapy
- When administered in a healthcare setting, appropriate medical treatment must be immediately available to manage potential anaphylactic reactions. When self-administered or administered by a caregiver, immediate medical attention should be sought if the vaccine recipient experiences symptoms of an allergic reaction
- In clinical trials, the risks of hospitalization and wheezing were increased in children younger than 2 years of age who received FLUMIST
- Children younger than 5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following the administration of FLUMIST. FLUMIST has not been studied in persons with severe asthma or active wheezing
- If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FLUMIST should be based on careful consideration of potential benefits and risks
- The effectiveness of FLUMIST has not been studied in immunocompromised persons
- The safety of FLUMIST in individuals with underlying medical conditions that may predispose them to complications following wild-type influenza infection has not been established

Please see additional Important Safety Information on the next page, and read the full Prescribing Information, including Patient Information and Instructions for Use.

1. Get Started & Learn More About FluMist

FluMist.com will include educational resources and support for patients to begin the ordering process.

2. Order FluMist Through an Online Pharmacy

Patient completes a medical questionnaire to determine eligibility for FluMist for themselves and anyone else in the order.

3. Confirming Eligibility

A healthcare professional will review the medical questionnaire to determine eligibility. Once confirmed the prescription will be filled.

4. Shipping & Delivery

FluMist will be shipped in controlled temperature packaging on the date selected by the patient.

Tracking updates and/or delivery notifications will be provided by email & text.

5. Handling & Administration

FluMist will arrive with instructions on how to store and administer. Resources and support are available for patients.

6. Disposal of FluMist Sprayer & Packaging

After administration, the single-use FluMist sprayer(s) should be disposed of using the prepaid return envelope included in the packaging.

Reporting Vaccination Status Through Immunization Information Systems (IIS)

Adult confirms administration of the vaccine. Pharmacy then reports vaccination to IIS.^{4-7,a}



Adult



ASPN website



Reporting service



Registries



CDC Dashboard

Documentation is available to patients and their health care providers.^{4,b}

^aAfter patient consent, when applicable. ^bIf contact information provided.
CDC=Centers for Disease Control and Prevention

IMPORTANT SAFETY INFORMATION (continued)

- FLUMIST may not protect all individuals receiving the vaccine
- The most common solicited adverse reactions ($\geq 10\%$ in vaccine recipients and at least 5% greater than in placebo) reported after FLUMIST were runny nose or nasal congestion (ages 2-49 years), fever $>100^\circ\text{F}$ (children ages 2-6 years), and sore throat (adult ages 18-49 years)

INDICATION

FLUMIST is a vaccine indicated for active immunization of persons 2 through 49 years of age for the prevention of influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUMIST is for intranasal administration only.

Please see full [Prescribing Information](#), including [Patient Information](#) and [Instructions for Use](#).

You may report side effects related to AstraZeneca products [here](#).

References: 1. FLUMIST Prescribing Information. 2. Centers for Disease Control and Prevention. FluVaxView. Influenza Vaccination Coverage, Children 6 months through 17 years, United States. Accessed March 10, 2025. <https://www.cdc.gov/fluview/view/dashboard/children-vaccination-coverage.html>. 3. Centers for Disease Control and Prevention. FluVaxView. Influenza Vaccination Coverage and Intent for Vaccination, Adults 18 Years and Older, United States. Accessed March 10, 2025. <https://www.cdc.gov/fluview/view/dashboard/adult-coverage.html>. 4. In House data, AstraZeneca. Data on File. REF-263898. 5. Centers for Disease Control and Prevention. Immunization Information Systems Resources. May 17, 2024. Accessed February 26, 2025. https://www.cdc.gov/iis/about/index.html#cdc_data_surveillance. 6. Centers for Disease Control and Prevention. Influenza vaccine administration and coverage by jurisdiction, children and adults, United States. February 19, 2025. Accessed March 13, 2025. <https://www.cdc.gov/fluview/view/dashboard/vaccine-administration-coverage-jurisdiction-iis.html>. 7. IIS Policy and Legislation. Centers for Disease Control and Prevention. <https://www.cdc.gov/iis/policy-legislation/index.html#:~:text=Consent%20policies%20may%20differ%20for,included%20in%20the%20IIS%3B%20or>.